MYB and leukemia: Because of the co-expression of different SRC kinase family members in leukemia cells, their functional redundancies and the promiscuity of many of the available SRC-family kinase inhibitors makes it a daunting task to unravel the underlying molecular mechanisms we can currently only speculate on how they inhibit MYB activity.